TY - JOUR
T1 - Clinical Significance of Pretherapeutic Serum Squamous Cell Carcinoma Antigen Level in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
AU - Okamura, Akihiko
AU - Matsuda, Satoru
AU - Mayanagi, Shuhei
AU - Kanamori, Jun
AU - Imamura, Yu
AU - Irino, Tomoyuki
AU - Kawakubo, Hirofumi
AU - Mine, Shinji
AU - Takeuchi, Hiroya
AU - Kitagawa, Yuko
AU - Watanabe, Masayuki
N1 - Funding Information:
Akihiko Okamura, Satoru Matsuda, Shuhei Mayanagi, Jun Kanamori, Yu Imamura, Tomoyuki Irino, Hirofumi Kawakubo, Shinji Mine, Hiroya Takeuchi, Yuko Kitagawa, and Masayuki Watanabe have declared no conflicts of interests in respect of this study. However, conflicts of interest outside this work are as follows: Yuko Kitagawa received research funding from Taiho Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Merck Serono, Asahi Kasei, EA Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, Otsuka Pharmaceutical Factory, Shionogi, Kaken Pharmaceutical, Kowa Pharmaceutical, Astellas Pharma, Medicon, Dainippon Sumitomo Pharma, Taisho Toyama Pharmaceutical, Kyouwa Hakkou Kirin, Pfizer Japan, Ono Pharmaceutical, Nihon Pharmaceutical, Japan Blood Products Organization, Medtronic Japan, and Sanofi K.K, as well as grants from Eisai, Tsumura, KCI Licensing, Abbott Japan, and Fujifilm Toyama Chemical.
Publisher Copyright:
© 2020, Society of Surgical Oncology.
PY - 2021/2
Y1 - 2021/2
N2 - Background: Although squamous cell carcinoma antigen (SCC-Ag) is a tumor marker widely used to estimate the progression of esophageal SCC (ESCC), only a few studies have focused on the relationship between serum SCC-Ag levels and the therapeutic effect of neoadjuvant chemotherapy (NAC). Objective: This study aimed to elucidate the clinical significance of pretherapeutic serum SCC-Ag levels in patients who underwent NAC followed by esophagectomy. Methods: Data of 453 patients who underwent NAC followed by esophagectomy were collected from the esophageal cancer database of two high-volume Japanese centers. Serum SCC-Ag levels were measured prior to NAC, and the pathological therapeutic effect of NAC and patient survival were evaluated. Patients were classified according to the tertiles of the serum SCC-Ag value (low, middle, and high groups), and the outcomes among the groups were compared. Results: The levels of serum SCC-Ag were significantly associated with tumor stage (p < 0.01). With regard to the pathological therapeutic effect, the levels of serum SCC-Ag were negatively correlated with the therapeutic effect (p = 0.02). Moreover, increased levels of serum SCC-Ag negatively influenced relapse-free survival (p < 0.01). Multivariate analyses revealed the ‘high’ group as the independent factor for both the unfavorable therapeutic effect (p = 0.01) and the increased risk of disease recurrence (p < 0.01) when compared with the ‘low’ group. Conclusion: Elevated levels of pretherapeutic serum SCC-Ag are significantly associated with advanced tumor stage, poor response to NAC, and increased risk of disease recurrence.
AB - Background: Although squamous cell carcinoma antigen (SCC-Ag) is a tumor marker widely used to estimate the progression of esophageal SCC (ESCC), only a few studies have focused on the relationship between serum SCC-Ag levels and the therapeutic effect of neoadjuvant chemotherapy (NAC). Objective: This study aimed to elucidate the clinical significance of pretherapeutic serum SCC-Ag levels in patients who underwent NAC followed by esophagectomy. Methods: Data of 453 patients who underwent NAC followed by esophagectomy were collected from the esophageal cancer database of two high-volume Japanese centers. Serum SCC-Ag levels were measured prior to NAC, and the pathological therapeutic effect of NAC and patient survival were evaluated. Patients were classified according to the tertiles of the serum SCC-Ag value (low, middle, and high groups), and the outcomes among the groups were compared. Results: The levels of serum SCC-Ag were significantly associated with tumor stage (p < 0.01). With regard to the pathological therapeutic effect, the levels of serum SCC-Ag were negatively correlated with the therapeutic effect (p = 0.02). Moreover, increased levels of serum SCC-Ag negatively influenced relapse-free survival (p < 0.01). Multivariate analyses revealed the ‘high’ group as the independent factor for both the unfavorable therapeutic effect (p = 0.01) and the increased risk of disease recurrence (p < 0.01) when compared with the ‘low’ group. Conclusion: Elevated levels of pretherapeutic serum SCC-Ag are significantly associated with advanced tumor stage, poor response to NAC, and increased risk of disease recurrence.
UR - http://www.scopus.com/inward/record.url?scp=85086336883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086336883&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-08716-y
DO - 10.1245/s10434-020-08716-y
M3 - Article
C2 - 32524457
AN - SCOPUS:85086336883
SN - 1068-9265
VL - 28
SP - 1209
EP - 1216
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 2
ER -
